纳米抗肿瘤药物载体的研究进展  

Progress in antitumor nano-drug carrier

作　　者：于东 王晓欣 姜如娇 YU Dong;WANG Xiaoxin;JIANG Rujiao(Graduate College, Dalian Medical University, Dalian 116044, Liaoning Province, China;Institute of Gene Engineering Animal Models of Human Diseases, Dalian Medical University, Dalian 116044, Liaoning Province, China)

机构地区：[1]大连医科大学研究生院,辽宁大连116044 [2]大连医科大学重大疾病基因工程模式动物研究所,辽宁大连116044

出　　处：《肿瘤》2018年第6期603-609,共7页Tumor

摘　　要：恶性肿瘤是全球性的公共健康问题,其发病率正呈逐年攀升的趋势。随着纳米技术和肿瘤分子生物学研究的发展,小分子纳米靶向抗恶性肿瘤药物的研究也在如火如荼的进行中。小分子纳米靶向药物依托纳米载药系统,一方面由于其能够增加药物的稳定性、生物利用度和靶向性,同时也因具有较好的可降解性,已引起广大研究者的广泛关注。本文分析了目前常用的3种抗肿瘤纳米载药系统(脂质体载药系统、聚合物胶束载药系统和无机纳米离子载药系统),并对这3种载药系统的制备方法、研究现状以及上市药物等进行了讨论。As a global public health problem, the incidence of malignant tumors is increasing year by year. With the development of nanotechnology and t relate the n u d mor molecular to small ano-drug molec delive biology, there a ular nano-targete re many growing d antitumor drugs. researches Relying on ry system, the small molecular nano-targeted drugs have some advantages. On the one hand, the nano-drug delivery system can increase the stability, bioavailability and targeting of drugs. On the other hand, the nano-drug delivery systems also have better degradability. This review focuses on the three common antitumor nano-drug carrier systems （including liposome drug delivery system, polymer micellar loading system and inorganic nano-ion carrier system）, and discusses their preparation methods, research status and the condition of going on sale.

关 键 词：肿瘤 纳米复合物 抗肿瘤药 分子靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]